Description of Medical ServiceImmunohistochemistry (IHC) test for evaluation of Programmed Cell Death-Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The biopsy sample taken as part of a standard diagnostic process will be used for immunohistochemical testing with PD-L1. The testing would be done by a pathologist alongside other immunohistochemical tests which are done routinely.
Description of Medical ConditionRecurrent or metastatic head and neck squamous cell carcinoma. Head and neck cancer includes tumours arising from the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid and salivary glands. Individuals who have progressed following initial definitive treatment have recurrent disease and require subsequent treatment. Patient who present with metastatic disease generally receive the same therapy as those with recurrent disease following initial definitive treatment.
Reason for ApplicationNew MBS item
Medical Service TypePBAC Co-dependent technology
Previous Application Number1522
Application FormRefer to previous application
Consultation SurveyConsultation Survey (PDF 684 KB)
Consultation Survey (Word 72 KB)
PICO ConfirmationRefer to previous application
Public Summary DocumentPublic Summary Document (PDF 1037 KB)
Public Summary Document (Word 566 KB)